CHICAGO—Results from the largest and longest trial of its kind suggest that patients with intermediate and advanced hepatocellular carcinomas who undergo systematic treatment with three chemotherapeutic agents and arterial embolization plus imaging follow-up have better survival rates than those who undergo nonstandardized chemoembolization regimes.
The treatment of patients with nonresectable liver malignancies using transcatheter arterial chemoembolization (TACE) has achieved widespread popularity worldwide. The type of drug and treatment management protocols used, however, can also be just as diverse.
Th is lack of standardized TACE protocols could significantly aff ect treatment outcomes, according to Dr. Liapi.
Retrospectively from 1996 to 2000 and prospectively from 2001 to 2007, Dr. Liapi and colleagues enrolled 347 patients with unresectable HCC who were 65.6 years old on average. All patients underwent a standardized protocol including MRI and/or CT at baseline; an average of three TACE sessions spaced out by about 80 days; and clinical, biochemical, and imaging evaluations before each TACE session. Finally, imaging follow-up was done.
The TACE protocol included doxorubicin(Drug information on doxorubicin), cisplatin, and mitomycin-C mixed with lipiodol followed by embolization with alcohol(Drug information on alcohol)" target="_blank">polyvinyl alcohol(Drug information on polyvinyl alcohol) or microspheres, avoiding complete vessel occlusion. Researchers evaluated disease status before and aft er treatment and measured tumor size using RECIST.
The investigators found that patients who completed the standardized treatment and follow-up protocol had stable liver disease and effective tumor control. In addition, these patients achieved average survival rates of nearly two years.
“Achieving 20 months median survival in a population that had 3% to 4% vascular invasion is commendable and quite a bit different from a lot of the other reports on survival from patients who have vascular invasion,” commented session chair William S. Rilling, MD.
TACE has already been proven as an eff ective treatment for patients with unresectable HCC, according to Dr. Liapi. But the comprehensive standardized protocol used at Hopkins for over a decade has been shown to bolster its effectiveness. Controlled randomized studies comparing different protocols would be ideal to validate the best treatment.
These are hard to come by, however, mostly due to ethical considerations, Dr. Liapi said.
“Right now, we are at the stage that we cannot perform that. So our best bet would be to just present as many patients as we can and show how these patients did over time,” she said.
